
Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, Japan, October 16, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that it was granted approval for “myasthenia...
Tokyo, Japan, October 16, 2009 - AstraZeneca K.K. (headquarters: Tokyo; President and CEO: Masuhiro Kato) today announced that it received a Japanese manufacturing and marketing approval for...
Tokyo, Japan, October 7, 2009 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that Astellas and Boehringer Ingelheim Pharmaceuticals, Inc. (a US...
Read more about Astellas and Boehringer Ingelheim Reach Settlement with Impax on FLOMAX® Patent Case
Tokyo, Japan, September 25, 2009 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) today announced that Boehringer Ingelheim Pharmaceuticals, Inc. (“
Read more about ASTELLAS ANNOUNCES EXTENSION OF MARKET EXCLUSIVITY IN THE US FOR FLOMAX® CAPSULES
Tokyo, Japan, September 24, 2009 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) and its US affiliate Astellas Pharma US, Inc. (headquarters:...
Read more about ASTELLAS FILED LAWSUIT AGAINST VESICARE® GENERICFOR PATENT INFRINGEMENT IN THE US